Chrysos Corp. Ltd. (AU:C79)
ASX:C79
Want to see AU:C79 full AI Analyst Report?
Top Page
Chrysos Corp. Ltd.
(Sydney:C79)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$5.50
▼(-24.97% Downside)
Action:Reiterated
Date:05/22/26
The score is held back primarily by weak profitability and cash flow (negative net margin and negative free cash flow), reinforced by bearish technicals with price below key moving averages and negative MACD. A stable, low-leverage balance sheet and strong revenue growth provide support, but valuation is a major headwind given the very high P/E and no dividend yield provided.
Positive Factors
Exceptional gross margin
An exceptionally high gross margin (99.97%) implies Chrysos's PhotonAssay has low incremental costs and strong product-level pricing power. This durable margin cushion supports reinvestment in R&D and service infrastructure as deployments scale, improving long-term unit economics.
Negative Factors
Negative net margin
Negative net margin (-12.44%) and a declining EBIT margin show Chrysos has not yet converted strong gross margins into operating profitability. Persistent operating losses threaten equity levels and require sustained margin improvement or higher revenue scaling to deliver durable shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Exceptional gross margin
An exceptionally high gross margin (99.97%) implies Chrysos's PhotonAssay has low incremental costs and strong product-level pricing power. This durable margin cushion supports reinvestment in R&D and service infrastructure as deployments scale, improving long-term unit economics.
Read all positive factors
Chrysos Corp. Ltd. (C79) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$643.02M
Dividend YieldN/A
Average Volume (3M)347.84K
Price to Earnings (P/E)293.0
Beta (1Y)1.61
Revenue Growth-86.60%
EPS Growth-2255.56%
CountryAU
Employees200
SectorTechnology
Sector Strength88
IndustrySoftware - Application
Share Statistics
EPS (TTM)-0.04
Shares Outstanding116,488,800
10 Day Avg. Volume301,690
30 Day Avg. Volume347,840
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.73
Price to Sales (P/S)8.20
P/FCF Ratio-9.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$8.90Price Target Upside21.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.02
Revenue Forecast (FY)AU$89.69M
Chrysos Corp. Ltd. Business Overview & Revenue Model
Company Description
Chrysos Corporation Limited engages in the development and supply of mining technology. It offers PhotonAssay, a technology for analysis of gold, silver, copper, and other elements. The company was incorporated in 2016 and is headquartered in Adel...
How the Company Makes Money
Chrysos makes money primarily by commercializing its PhotonAssay technology via customer deployments of its photon assay units and associated services. Revenue is generated from (i) fees tied to the use of PhotonAssay units (typically structured a...
Chrysos Corp. Ltd. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 155.00K | 66.11M | 45.36M | 26.82M | 571.00K | 47.00K |
| Gross Profit | -60.47M | 66.09M | 34.42M | 25.73M | 29.00K | -6.78M |
| EBITDA | -18.18M | 17.34M | 11.68M | 5.09M | 2.16M | -1.03M |
| Net Income | -4.88M | -8.22M | -704.00K | 443.00K | -3.94M | -3.84M |
Balance Sheet | ||||||
| Total Assets | 286.22M | 264.31M | 243.26M | 163.41M | 144.09M | 29.51M |
| Cash, Cash Equivalents and Short-Term Investments | 21.57M | 21.52M | 61.07M | 53.36M | 92.10M | 5.77M |
| Total Debt | 55.10M | 25.41M | 6.67M | 14.28M | 8.82M | 3.14M |
| Total Liabilities | 87.85M | 66.01M | 44.99M | 39.18M | 21.77M | 15.28M |
| Stockholders Equity | 198.38M | 198.30M | 198.27M | 124.23M | 122.32M | 14.23M |
Cash Flow | ||||||
| Free Cash Flow | -47.62M | -59.89M | -56.23M | -42.61M | -25.67M | -7.46M |
| Operating Cash Flow | 7.19M | 8.83M | 3.63M | 4.65M | 1.41M | 613.00K |
| Investing Cash Flow | -57.21M | -68.72M | -59.86M | -47.26M | -26.98M | -8.07M |
| Financing Cash Flow | 46.23M | 17.28M | 64.30M | 3.54M | 111.52M | -268.00K |
Chrysos Corp. Ltd. Technical Analysis
Negative
7.33
Price Trends
7.21
Negative
7.61
Negative
7.59
Negative
Market Momentum
-0.46
Positive
23.68
Positive
5.16
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:C79, the sentiment is Negative. The current price of 7.33 is above the 20-day moving average (MA) of 6.76, above the 50-day MA of 7.21, and below the 200-day MA of 7.59, indicating a bearish trend. The MACD of -0.46 indicates Positive momentum. The RSI at 23.68 is Positive, neither overbought nor oversold. The STOCH value of 5.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:C79.
Chrysos Corp. Ltd. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
54 Neutral | AU$438.68M | 13.57 | 4.13% | ― | 4.45% | ― | |
49 Neutral | AU$11.77M | 5.74 | -2.67% | ― | 25.60% | 76.00% | |
48 Neutral | AU$25.17M | -3.90 | -27.05% | ― | 4.41% | 19.30% | |
44 Neutral | AU$643.02M | 293.00 | -2.46% | ― | -86.60% | -2255.56% | |
42 Neutral | AU$24.56M | -3.76 | 190.04% | ― | -42.72% | ― | |
42 Neutral | AU$51.04M | -1.75 | -60.02% | ― | 15.14% | -102.70% |
* Technology Sector Average
AU:C79
Chrysos Corp. Ltd.
5.83
1.20
25.92%
AU:3DP
Pointerra
0.03
-0.03
-47.37%
AU:AMX
Aerometrex Ltd.
0.27
-0.02
-5.36%
AU:VR1
Vection Technologies Ltd.
0.03
<0.01
19.05%
AU:1CG
UUV Aquabotix Ltd.
0.01
0.00
0.00%
AU:NXL
Nuix Ltd.
1.33
-1.12
-45.70%
Chrysos Corp. Ltd. Corporate Events
Chrysos Hits Record Assay Volumes as Lease Deals and Global Deployments Accelerate
May 3, 2026
Chrysos Corporation reported record operational performance, with its PhotonAssay™ fleet processing more than one million samples in both March and April 2026, marking a new utilisation high that supports accelerated average assay charges an...
ECP Asset Management Ceases to Be Substantial Holder in Chrysos Corporation
Mar 31, 2026
ECP Asset Management, EC Pohl Co and associated entities have lodged a notice stating they have ceased to be substantial holders in Chrysos Corporation Limited as of 27 March 2026. The change reflects a reduction in their relevant voting interest...
Chrysos Director Robert Adamson Trims Direct Shareholding in On-Market Trade
Mar 27, 2026
Chrysos Corporation Limited disclosed a change in the shareholding of director Robert Henry Richard Adamson, who holds interests both directly and via family investment vehicles. The filing details his control over shares held by the Adamson Famil...
Chrysos Seeks ASX Quotation for Additional 12,500 Shares
Mar 16, 2026
Chrysos Corporation Limited has applied for quotation on the ASX of 12,500 ordinary fully paid shares under its existing ticker C79. The new securities, issued on March 11, 2026, arise from the exercise or conversion of existing options or other c...
Chrysos Director Eric Ford Increases Indirect Stake via Option Exercise
Mar 16, 2026
Chrysos Corporation has disclosed a change in the interests of director Eric Ford, following the exercise of 12,500 options at $4.50 per share and the subsequent acquisition of an equivalent number of fully paid ordinary shares. The new shares, in...
Chrysos Corporation Reports Lapse of 2,107 Performance Rights
Mar 4, 2026
Chrysos Corporation Limited has reported the lapse of 2,107 performance rights, which ceased on 28 January 2026 after conditions attached to the rights were not satisfied or became incapable of being met. The notification reflects a small adjustme...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.